RAM (RYAM) Q3 2026 Earnings Call Transcript

Rayonier Advanced Materials reported Q3 net sales of $383 million, up 8% year over year, and Adjusted EBITDA of $52 million, up 30% sequentially; its $229 million loss from continuing operations included $221 million of non-cash impairments, primarily related to Témiscaming. The facility was economically idled on October 3 after a 50% U.S. tariff on Canadian paperboard took effect, with carrying costs estimated at $2 million-$3 million per month. Management extended its strategic review target to Q1 2027 and is pursuing a shift toward higher-margin Cellulose Specialties, while full-year specialty volumes are expected to remain below prior-year levels.

Analysis

The key valuation issue is whether a specialty-led earnings profile can be separated from the commodity and site liabilities—not whether the specialty franchise can command a premium price. The pricing premium is not yet evidence of scalable earnings: specialty volumes remain weak, and management’s willingness to balance price against volume creates execution and customer-retention risk. A mix shift only creates value if capacity, customer commitments, and mill economics permit it without discounting away the premium.

Témiscaming is both a direct cash drag and a transaction-friction problem. Continued idling costs compound while buyers assess the site’s options; the longer the review extends beyond Q1 2027, the more leverage and liquidity can overwhelm the franchise narrative. The impairment is non-cash, but it does not resolve the cash burden. Conversely, a credible site solution could make the remaining business easier to value and reduce the conglomerate discount.

Near term, the review is the dominant catalyst; the management-buyout interest is not a committed bid or reliable floor. Over 1–3 months, watch for review progress, tariff developments, and evidence that specialty volumes approach the exit-rate target. Over 6–18 months, the thesis depends on sustained mix improvement and cash generation. The contrarian risk is that investors capitalize the stated specialty value before it appears in consolidated cash flow. No clean peer hedge is justified without comparable valuation and exposure data.

Key Decisions for Investors

• Keep RYAM as an event-driven watch, not a core long: avoid adding ahead of a disclosed transaction or demonstrable operating conversion, given 4.0x secured leverage, limited liquidity, and uncertain review timing.
• Reassess only on verifiable catalysts: a binding strategic outcome or quantified Témiscaming plan, alongside specialty-volume progress and positive free cash flow that is not chiefly working-capital timing or credits.
• Treat a review delay beyond Q1 2027, continued specialty-volume weakness, or liquidity deterioration as thesis-negative; these would increase the risk that site costs and financing constraints capture more value than the specialty franchise creates.
• Do not infer that the non-cash impairment is a cash-flow fix. Track monthly Témiscaming carrying costs and available ABL/factoring capacity; a sustained increase in costs or reduced access to liquidity would warrant a more defensive stance.